VEA - Vanguard FTSE Developed Markets ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
45.24
-0.21 (-0.46%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close45.45
Open45.43
Bid0.00 x 0
Ask0.00 x 0
Day's Range45.13 - 45.47
52 Week Range39.06 - 47.89
Volume6,195,075
Avg. Volume11,595,787
Net Assets108.64B
NAV44.16
PE Ratio (TTM)N/A
Yield2.84%
YTD Return-1.00%
Beta (3y)0.90
Expense Ratio (net)0.07%
Inception Date2007-07-20
Trade prices are not sourced from all markets
  • InvestorPlace13 hours ago

    7 Vanguard ETFs for Buy-and-Hold Investors

    Compared to rivals such as iShares and State Street’s SPDR brand, Vanguard’s lineup of exchange-traded funds (ETFs) is small.

  • Benzinga8 days ago

    Demand For International ETFs Remains Strong

    One of the more notable themes in the world of exchange-traded funds last year was investors affinity for international equity funds. When 2017 drew to a close, five of the year's top 10 asset-gathering ...

  • Wining ETF Areas of March
    Zacks18 days ago

    Wining ETF Areas of March

    Inside the ETFs that raked in sizable assets in March.

  • Barrons.com27 days ago

    [$$] The Municipal Route

    Michael Hershey probably could have made a nice career out of selling real estate investments, but his clients needed more. “I started getting phone calls at night from clients, asking, ‘Can I afford this new car? Should I buy this sofa?’ ” says the JPMorgan advisor, who is Barron’s 21st-ranked advisor in Washington state.

  • March Madness ETF Prediction and Sweet 16 Picks
    Zacks29 days ago

    March Madness ETF Prediction and Sweet 16 Picks

    The excitement surrounding the tournament and its impact on the stock world has led investors to look at ETFs that could act as a proxy for the game.

  • Investopedialast month

    Short Interest Rises in Popular International, Bond ETFs

    Ahead of this week's Fed meeting, short interest rose in some rate-sensitive ETFs.

  • Barrons.comlast month

    [$$] Values and Profit Meet Up

    When Charles Brighton and his partner Jon Jones began talking up sustainable investing six years ago, they figured they’d mostly get uptake from their core clients—young, idealistic tech professionals around their Seattle offices. In just a few years, Brighton Jones has transitioned 10% of its $4.6 billion in assets to sustainable investing. “I can see a day coming, maybe a few years from now, when we say, ‘Let’s go all impact.’ ” Sustainable investing is growing fast as an investment category.

  • Weekly ETF Roundup: International & Bond Win, US Equity Lags
    Zacks2 months ago

    Weekly ETF Roundup: International & Bond Win, US Equity Lags

    Inside the ETFs that gained investor's attraction last week.

  • Novartis’s 4Q17 Earnings: Alcon Business
    Market Realist2 months ago

    Novartis’s 4Q17 Earnings: Alcon Business

    Must-Read Notes on Novartis’s 4Q17 and 2017 Earnings

  • Multiple Myeloma May Be Strong Growth Area for GlaxoSmithKline
    Market Realist2 months ago

    Multiple Myeloma May Be Strong Growth Area for GlaxoSmithKline

    GlaxoSmithKline (GSK) estimates that almost 65% of the global multiple myeloma (or MM) drug sales are realized in the US. The demand in the MM segment is mainly driven by the aging population, which has resulted in rising annual incidence by around 2% for the disease. Currently, Johnson & Johnson’s (JNJ) anti-CD38 monoclonal antibody, Darzalex (daratumumb) is witnessing rapid uptake in the MM segment due to its higher efficacy as compared to the previous standard of care therapy.

  • AstraZeneca’s 4Q17 Earnings: Analyst Estimates
    Market Realist3 months ago

    AstraZeneca’s 4Q17 Earnings: Analyst Estimates

    AstraZeneca’s 4Q17 Earnings on February 2: What to ExpectA look at AstraZeneca

  • 2-Drug HIV Regimens Expected to Boost GlaxoSmithKline’s Revenues
    Market Realist3 months ago

    2-Drug HIV Regimens Expected to Boost GlaxoSmithKline’s Revenues

    On November 21, 2017, the U.S. Food and Drug Administration (or FDA) approved Jucala, a two-drug oral regimen comprising of dolutegravir and rilpivirine for patients suffering with HIV-1 infections who have not demonstrated treatment failure or history of drug resistance to the individual components of the new therapy. Juluca is commercialized by ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK), Pfizer (PFE), and Shinogi. Since the current standard of care includes three or more drugs, the two drug regimen could help reduce toxicity levels for treated patients.

  • GlaxoSmithKline Could Witness Modest Rise in Revenues in 2017
    Market Realist3 months ago

    GlaxoSmithKline Could Witness Modest Rise in Revenues in 2017

    GlaxoSmithKline (GSK) is a leading player in the global respiratory market with a major focus on the asthma and chronic obstructive pulmonary disease (or COPD) segments. The company has estimated global asthma prevalence to be around 250 million with 40% of the treated patients continuing to witness symptoms that affect the quality of their lives. To capitalize on this unmet demand, GlaxoSmithKline aims to deliver the right inhaled corticosteroid (or ICS) or combination regimen to the right patients and to ensure proper drug adherence.

  • Key Updates on Novartis’s Kymriah
    Market Realist3 months ago

    Key Updates on Novartis’s Kymriah

    How Novartis Is Positioned for 2018

  • Reading the Estimates for Novartis’s Alcon in 4Q17
    Market Realist3 months ago

    Reading the Estimates for Novartis’s Alcon in 4Q17

    Novartis’s 4Q17 Earnings: Behind the Expectations

  • Zelboraf Could Boost Roche’s Sales Growth in 2018
    Market Realist3 months ago

    Zelboraf Could Boost Roche’s Sales Growth in 2018

    What to Expect from Roche in 2018

  • How Is Roche’s Hemlibra Positioned for 2018?
    Market Realist3 months ago

    How Is Roche’s Hemlibra Positioned for 2018?

    What to Expect from Roche in 2018

  • What to Expect from Roche’s Investigational Drug Polatuzumab Vedotin
    Market Realist3 months ago

    What to Expect from Roche’s Investigational Drug Polatuzumab Vedotin

    What to Expect from Roche in 2018

  • U.S. Listed ETFs Garner Record Inflows in 2017
    Zacks3 months ago

    U.S. Listed ETFs Garner Record Inflows in 2017

    U.S. equity and International equity ETF among top gainers in fund inflows in 2017.

  • 7 Low-Cost Vanguard ETFs to Kick-Start Your Portfolio in 2018
    InvestorPlace3 months ago

    7 Low-Cost Vanguard ETFs to Kick-Start Your Portfolio in 2018

    2017 was another record year for assets flowing into exchange-traded funds (ETFs), and Vanguard was a big reason why. When it came to lost assets, not one Vanguard ETF was among last year’s worst offenders. By some estimates, Vanguard could be managing $10 trillion in total assets by 2023.

  • Benzinga4 months ago

    A Cheap International ETF And Its Epic Growth Spurt

    There is no denying investors' thirst for international exchange traded funds in 2017. As the U.S. bull market ages,  investors are are flocking to low-fee ex-U.S. ETFs in search of new frontiers for potential ...

  • Why ETFs Are Thriving in 2017
    Zacks4 months ago

    Why ETFs Are Thriving in 2017

    The ETF industry has gathered more than $600 billion in new assets in the first 11 months of 2017.

  • Market Realist4 months ago

    Analysts’ Recommendations for GlaxoSmithKline in November 2017

    Wall Street analysts estimate that GlaxoSmithKline’s (GSK) top line could fall 0.8% to ~7.5 billion pounds in 4Q17.